The application provides methods for generating a therapeutic composition. In one embodiment, the method includes the steps of providing a cell material comprising a cytotoxic cell, incubating the cell material with a first GNC protein to provide an activated cell composition, wherein the activated cell composition comprises a first therapeutic cell, and formulating the activated cell composition to provide a therapeutic composition, wherein the therapeutic composition is substantially free of exogenous viral and non-viral DNA or RNA. The first GNC protein comprises a first cytotoxic binding moiety and a first cancer targeting moiety, wherein the first cytotoxic binding moiety has a specificity to a first cytotoxic cell receptor and is configured to activate the first cytotoxic cell through the binding with the first cytotoxic cell receptor, and wherein the first cancer targeting moiety has a specificity to a first cancer cell receptor. The first therapeutic cell comprises the first GNC protein bound to the cytotoxic cell through the binding interaction with the first cytotoxic cell receptor.本申請案提供用於產生治療組合物之方法。在一個實施例中，該方法包括以下步驟：提供包含細胞毒性細胞之細胞材料，用第一GNC蛋白質培養該細胞材料以提供活化細胞組合物，其中該活化細胞組合物包含第一治療細胞，及調配該活化細胞組合物以提供治療組合物，其中該治療組合物實質上不含外來的病毒及非病毒DNA或RNA。該第一GNC蛋白質包含第一細胞毒性結合部分及第一癌症靶向部分，其中該第一細胞毒性結合部分具有對第一細胞毒性細胞受體之特異性且經配置以經由與該第一細胞毒性細胞受體結合來活化該第一細胞毒性細胞，且其中該第一癌症靶向部分具有對第一癌細胞受體之特異性。該第一治療細胞包含該第一GNC蛋白質，其經由與該第一細胞毒性細胞受體的結合相互作用結合至該細胞毒性細胞。
